Home

Articles from Attovia Therapeutics, Inc.

Attovia Therapeutics Announces First Participant Dosed in First-in-Human Phase 1 Study of ATTO-1310, its Novel Half-life Extended Anti-IL-31 ATTOBODY for the Treatment of Chronic Pruritus
ATTO-1310 offers a potential treatment for pruritic indications like CPUO where no approved treatments exist, and the potential for best-in-disease efficacy across pruritic conditions
By Attovia Therapeutics, Inc. · Via GlobeNewswire · January 23, 2025
Attovia Therapeutics Appoints Chief Financial Officer
Steven Chan, an accomplished finance leader, joins Attovia as Chief Financial Officer
By Attovia Therapeutics, Inc. · Via GlobeNewswire · October 15, 2024
Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors
FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs. Gold and You are seasoned biotech executives and experienced board members who bring decades of industry leadership experience, including early- and late-stage therapeutic development and commercialization.
By Attovia Therapeutics, Inc. · Via GlobeNewswire · July 9, 2024
Attovia Therapeutics Raises $105 Million Oversubscribed Series B Financing Led by Goldman Sachs Alternatives
-- Proceeds support advancing Attovia’s lead programs through initial clinical readouts, expanding its pipeline, and ongoing development of the ATTOBODY™ platform
By Attovia Therapeutics, Inc. · Via GlobeNewswire · May 9, 2024
Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Clinical and Scientific Advisory Boards
-- Hubert Chen, accomplished drug developer and pharma executive, joins as Chief Medical Officer
By Attovia Therapeutics, Inc. · Via GlobeNewswire · March 26, 2024
Attovia Announces Second Tranche Closing of $60 Million Series A Financing and Highlights Progress Building a Best-in-Class Pipeline Leveraging the Attobody™ Platform
-- Financing supports building immunology and inflammation pipeline, advancing lead programs into the clinic and ongoing development of the Attobody platform
By Attovia Therapeutics, Inc. · Via GlobeNewswire · February 8, 2024